No Evidence of Dementia, Brain Atrophy With Antidepressant Use

Antidepressant medication use is not associated with long-term cognitive decline, brain atrophy, or dementia risk, according to results from a prospective cohort study published in Alzheimer’s and Dementia. Although antidepressants are used widely and have become more frequently used among older adults, the long-term effects of antidepressant use on cognition and dementia remain uncertain. To…

Read More

Researchers discover compounds produced by gut bacteria that can treat inflammation

Non-enzymatic production of diindoles. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-46559-3 Researchers at the University of Toronto have found naturally occurring compounds in the gut that can be harnessed to reduce inflammation and other symptoms of digestive issues. This can be achieved by binding the compounds to an important, but poorly understood, nuclear receptor. The gut…

Read More

iGlarLixi Safe and Effective in Inadequately Controlled T2D

TOPLINE: iGlarLixi, a fixed-ratio combination of insulin glargine and the glucagon-like peptide-1 receptor agonist (GLP-1 RA) lixisenatide, improves glycemic control, with a low rate of hypoglycemia, in adults with inadequately controlled type 2 diabetes (T2D). METHODOLOGY: The 2022 Consensus Statement from the American Diabetes Association/European Association for the Study of Diabetes suggests that a fixed-ratio…

Read More

Therapist Burnout Negatively Affects Patient Outcomes During Psychotherapy

Therapist burnout negatively affected the delivery of trauma-focused psychotherapies (TFPs) to patients with posttraumatic stress disorder (PTSD), according to study results published in JAMA Network Open. Clinicians who experience burnout have previously reported that their symptoms affect the quality of care they deliver, their communication with patients, and the likelihood of making a medical error….

Read More

Change Eligibility Rules for More Diverse Clinical Trials?

Expanding eligibility criteria is a strategy for improving the inclusion of traditionally underrepresented populations in clinical trials, according to a study. The results were published in NEJM Evidence by Maneet Kaur, PhD, epidemiologist and senior scientist at Flatiron Health, New York, and colleagues. Flatiron Health is an independent member company of the Roche group and…

Read More
error: Content is protected !!